Keyword: Aetna

Amazon's plan to jump into drug sales has hit a snag, and the retail giant has reportedly put at least one plan on ice.

Jockeying for market share, Eli Lilly offered more than half off its U.S. list prices in the form of rebates and discounts last year.

J&J paid out $15 billion in rebates and discounts in 2017 as its average selling price slipped 4.6%.

In the wake of the Aetna-CVS combo, Cigna's Express Scripts buy could mean more pricing resistance ahead for drugmakers.

Novartis' Entresto to treat heart failure had a tough launch at $4,600 a year, but the product is starting to turn around.

Add Merck to the list of companies participating in pay-for-performance deals. Facing stepped-up competition in diabetes, the pharma signed a value-based contract with leading insurer Aetna for its Januvia and Janumet.

Dealing a blow to Sarepta Therapeutics’ launch efforts, leading U.S. insurer Anthem has decided not to cover the pricey duchenne muscular dystrophy drug Exondys 51.

Harvard Pilgrim broke new ground in the pay-for-performance arena, striking a first-ever deal for Eli Lilly's diabetes med Trulicity and the latest outcomes-based arrangement on Novartis' Entresto.

Pharma may have pulled off only a few outcomes-based pricing deals with payers, but companies are likely to add more to that list soon--many more, if payers have their way.